With the new funding, AsclepiX will accelerate development of a lead therapy candidate that targets two leading causes of adult blindness.
from https://www.bizjournals.com/baltimore/news/2018/11/13/baltimore-biopharma-targeting-eye-diseases-raises.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/180079175487
No comments:
Post a Comment